Zineryt

Quick links to important sections

Zineryt

Treatment option: Blackheads

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zineryt

Property Description
Active ingredient Erythromycin and Zinc Sulfate
Form Topical solution (reconstituted)
Pharmacological class Macrolide antibiotic, Dermatological anti-acne agent
Common use Management of specific skin conditions
Origin Semi-synthetic, dual-agent combination

Zineryt: A Defined Combination and Pharmacological Class

Zineryt is a specialized topical solution classified as a fixed-dose combination product intended for direct skin application (the cutaneous route of administration). Its dual composition places it within the high-level pharmacological grouping of dermatological anti-acne agents. The formulation includes a macrolide antibiotic, a class widely utilized in medicine. Zineryt is designated as a Prescription-Only Medicine, which ensures its use is regulated and professionally supervised, distinguishing it from general cosmetic or over-the-counter products.

Composition and Origin: Erythromycin and Zinc Sulfate

The active ingredients in Zineryt are the macrolide antibiotic Erythromycin and Zinc Sulfate, specifically complexed as zinc acetate dihydrate. The formulation is provided as a powder and solvent that must be mixed immediately prior to use to yield the final topical solution. This pre-reconstitution format is a specific formulation choice designed to maintain the stability and efficacy of the components.

The two key components form an Erythromycin-Zinc complex, a mechanism that is clinically recognized for enhancing skin penetration compared to Erythromycin used alone, thereby improving drug delivery. The product contains essential excipients like Di-isopropyl sebacate and Ethanol which act as the base/vehicle.

General Purpose of the Dual-Action Formulation

The general therapeutic purpose of Zineryt is to leverage the synergistic action of its two components to manage specific dermatological conditions where bacterial factors and inflammation are present. The Erythromycin component primarily provides a bacteriostatic effect, meaning it limits the proliferation of susceptible bacteria on the skin, a property widely established in clinical practice.

The Zinc component contributes a crucial supportive role by imparting valuable astringent properties and mild anti-inflammatory effects, which help to stabilize the skin surface and reduce localized irritation. This integrated, dual-action approach—combining microbial control and surface modulation in a single application—is intended to offer comprehensive support for skin recovery.

Regulatory References

  1. World Health Organization
  2. National Institutes of Health

What side effects are possible with Zineryt?

Possible Side Effects and Safety Information

The regulatory safety profile for this topical solution is established by authoritative governmental sources and is primarily characterized by localized skin reactions. The classification of undesirable effects is based on the system organ class (SOC) and frequency of occurrence documented in official regulatory labeling.


Documented Adverse Reactions

Adverse reactions are mainly associated with the Skin and subcutaneous tissue disorders class. Effects classified as Uncommon (affecting up to 1 in 100 people) include localized manifestations such as Pruritus (itching), Erythema (redness), a Skin burning sensation, Dry skin, and Skin exfoliation (peeling). Reactions involving the Immune system disorders are documented, with Hypersensitivity classified as Very Rare (affecting up to 1 in 10,000 people).

A serious cutaneous adverse reaction reported is Acute generalised exanthematous pustulosis (AGEP), the frequency of which is classified as Not Known (cannot be estimated from the available data).


Official Safety Constraints

The product is contraindicated in individuals who have known hypersensitivity to the active ingredients (Erythromycin, Zinc Sulfate), to other antibiotics of the macrolide group, or to any of the product's excipients. Regulatory labeling advises that prolonged use of this anti-infective carries the risk of superinfection by resistant micro-organisms; consequently, a course should not usually exceed six months. Cross resistance may occur with other macrolides, lincomycin, and clindamycin.

Regarding special populations, the product may be used during pregnancy. For breast-feeding individuals, the medication is permitted, but it is explicitly noted that the product must not be used on the chest area.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information regarding Zineryt (Erythromycin/Zinc Acetate topical solution) overdose is defined by two primary scenarios: accidental oral ingestion and excessive topical use.

Documented Overdose Scenarios

Scenario Potential Manifestation Action Required (As Labeled)
Accidental Oral Ingestion Symptoms associated with alcohol intake (due to the anhydrous ethanol excipient). Contact a doctor or pharmacist immediately.
Excessive Topical Application Minimal or no systemic effects documented. Blot off the excess solution with a tissue.
Contact with Eyes/Mucous Membranes Local irritation. Rinse immediately with cold or lukewarm water and contact a doctor for further advice.

When to Seek Immediate Medical Help

Urgent medical guidance is required if the entire contents of a single pack are accidentally swallowed. In this situation, the primary concern is the toxicity resulting from the high concentration of ethanol in the excipient, which necessitates professional management.

There is no specific antidote listed in official regulatory documents for Zineryt overdose. Management for accidental ingestion is centered on supportive care for the resulting alcohol-related symptoms. For simple over-application to the skin, no urgent medical attention is needed, and the official instruction is to simply blot off the excess solution.

Therapeutic Uses of Zineryt

Main uses of Zineryt

Zineryt is a topical solution primarily used for the treatment of moderate to severe forms of acne vulgaris. It is specifically formulated to address cases where topical treatments without antibiotics have not been sufficiently effective.

The medication works through a combination of two active ingredients that target different aspects of acne development:

  • Erythromycin: An antibiotic that reduces the growth of Cutibacterium acnes, the bacteria associated with acne inflammation and breakouts.
  • Zinc acetate: A compound that aids in skin healing and, when combined with erythromycin, enhances the absorption of the antibiotic into the skin while potentially reducing the development of bacterial resistance.

Benefits and effects

Zineryt is designed to manage acne by addressing bacterial colonization and the subsequent inflammatory response. The clinical benefits observed during treatment include:

Reduction of inflammatory lesions

By inhibiting bacterial activity, the solution helps to reduce the redness, swelling, and pain associated with inflammatory acne lesions, such as papules and pustules.

Prevention of new breakouts

Regular application helps to control the bacterial population on the skin's surface and within the sebaceous glands, which can decrease the frequency and severity of new acne flare-ups.

Suitability for various skin areas

While most commonly used on the face, the solution is also suitable for treating acne located on the back and chest. Its liquid form allows for application over larger surface areas or areas with hair where creams or ointments might be less practical.

Synergy of active ingredients

The complex formed by erythromycin and zinc is more stable and penetrates the skin layers more effectively than erythromycin alone, ensuring that the active components reach the site of the infection within the pores.

Regulatory References

  1. Summary of Product Characteristics by the HPRA

Eligibility and Restrictions for Use

The eligibility for using Zineryt (Erythromycin and Zinc Sulfate topical solution) is determined by regulatory bodies, with rules focusing on age, known allergies, and reproductive status.

Contraindications and Eligibility

Classification Rule and Population Status in Labeling
Absolute Contraindications History of hypersensitivity to Erythromycin, Zinc, or any other macrolide antibiotics (e.g., Clarithromycin) or excipients. Must Not Use
Pediatric Use Children under 12 years of age. Not Recommended (Lack of data)
Approved Age Groups Adolescents (from 12 years of age), Adults, and the Elderly. Eligible

Conditional Use Populations

  • Pregnancy: The product should not be used unless the clinical condition of the woman requires treatment with erythromycin, based on professional risk-benefit assessment.
  • Breastfeeding: Use is permitted; however, the solution must not be applied to the chest area to prevent accidental ingestion by the infant.

Systemic conditions such as liver or kidney impairment do not have specific restrictions documented in the product's official labeling, owing to its topical application and minimal systemic absorption.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Zineryt (erythromycin and zinc acetate topical solution) has a limited interaction profile due to its external, cutaneous route of administration. Officially documented interaction constraints primarily relate to co-application of other topical preparations on the skin.

Interacting Products and Product Classes

Interaction Type Interacting Product Category Practical Regulatory Implication
Additive Local Irritation Other Topical Anti-Acne Preparations (especially peeling/abrasive agents) Concurrent use should be avoided to prevent cumulative irritancy, such as increased drying or exfoliation.
Potential Inactivation Topical Products with Acidic or Alkaline pH Contact with substances that are strongly acidic or alkaline (e.g., salicylic acid, urea) should be prevented, as the active ingredient erythromycin may be inactivated.
Cross-Resistance Other Macrolide Antibiotics (e.g., Lincomycin, Clindamycin) Use may promote cross-resistance to other antibiotics in the macrolide group, which is a consideration in the overall management of bacterial resistance.

Interaction-Related Constraints

The most significant constraint defined in regulatory documentation is the risk of cumulative skin irritation when this product is used at the same time as other topical agents with abrasive, desquamating, or peeling properties. This is a local drug-drug interaction that may manifest as increased dryness, redness, or burning. Official product information notes that no formal drug interaction studies have been performed; however, the avoidance of concurrent use with irritating topical treatments is a clear, standard constraint.

Mechanism of Action

The pharmacological action of Zineryt is based on two distinct, complementary pharmacodynamic mechanisms.

Inhibition of Microbial Proliferation via Ribosomal Binding

The macrolide component, Erythromycin, acts as a reversible inhibitor by targeting the bacterial 50S ribosomal subunit . Its binding blocks the nascent peptide exit tunnel, effectively arresting the elongation of the polypeptide chain. This action results in a bacteriostatic effect, meaning the mechanism halts the proliferation of susceptible bacteria, a mechanism that impacts the physiological conditions at the application site.

Zinc-Mediated Modulation of Inflammatory and Oxidative Pathways

The zinc component operates within the applied tissue to modulate local tissue response and cellular stabilization. Its mechanism involves modulation of local inflammatory signaling pathways, such as the NF-kappaB system, and the induction of antioxidant proteins (metallothioneins). This action suppresses the signaling cascade that releases pro-inflammatory mediators and neutralizes damaging free radicals, leading to the physiological consequence of decreased localized tissue response.

Synergistic Enhancement of Target Engagement

The active ingredients form an Erythromycin-Zinc complex that enhances the physical delivery and accumulation of the agents, particularly zinc, into the sebaceous glands. This synergistic feature ensures that the microbial control and pathway modulation mechanisms are executed efficiently and simultaneously at the site of biological activity, achieving a coordinated dual physiological action.

Dosage and Administration Information

Administration Guidelines for Zineryt

The instructions for using Zineryt (erythromycin/zinc acetate) define the specific preparation and application steps required for topical use.

Administration Scope

Feature Instruction
Route Cutaneous use (topical application to the skin).
Dosing Schedule Apply a thin layer over the whole of the affected area and the surrounding skin.
Frequency Twice a day (typically morning and evening).
Course Duration The normal treatment time is 10 to 12 weeks.

Preparation and Application

Zineryt is supplied as a powder and a solvent that must be mixed, or reconstituted, immediately before first use. The user or pharmacist must pour the solvent into the powder bottle, immediately shake well for one minute, and then fit the special dabbing applicator assembly onto the bottle.

Before application, the affected area of skin must be washed.

To apply, hold the bottle upside down, place the pad against the skin, and spread the solution over the entire area to be treated. Remove the protective cap before use and replace it firmly afterward. If make-up is to be used, the medicine should be allowed to dry completely before applying cosmetics.

Special Conditions

  • Accidental Contact: The solution must not contact the eyes or the mucous membranes of the nose and mouth. If accidental contact occurs, the area must be rinsed well with plenty of water.
  • Missed Dose: If an application is missed, apply the dose when remembered, but ensure there is a gap of about three hours before the next scheduled application.
  • Population: The medicine is indicated for use in children, adults and the elderly.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Efficacy in Monotherapy

Studies evaluated the effect of this medication, which combines the antibiotic erythromycin and zinc acetate, on the primary symptoms of acne vulgaris in adult participants.

  • The evaluated studies involved patients who had not previously used a drug for this condition.
  • The change in symptom severity observed in participants was analyzed.
  • The data reported variations in measurements taken on symptom scores across different trials.

Investigated Effects on Quality of Life

Studies evaluated the effect on fatigue levels and general well-being in patients with acne. This was examined in relation to changes during flare-ups.

  • One study protocol focused on changes in participants' self-reported ability to perform daily activities.
  • The comparison of data showed an alignment between a lower symptom score and self-reported improvements in quality of life metrics.
  • Long-term data regarding sustained quality of life effects were not consistently reported in the reviewed studies.

Safety and Patient Profile Evaluated

The safety profile was assessed in the evaluated populations.

  • Studies included patients with mild liver impairment, but did not include people with severe impairment.
  • The most frequently reported adverse events included temporary headaches and gastrointestinal upset.
  • Comparative research on this medication against other treatments was not included in the documentation reviewed.

Combination Therapy: Research on Long-Term Outcomes

Studies evaluated the use of the medication in combination with a standard care regimen.

  • Studies examined the combination's effect on specific physiological measurements which were considered exploratory outcomes.
  • The study protocol involved participants continuing the regimen for periods up to six months.
  • Data on long-term outcomes were collected and analyzed for differences between the monotherapy and combination groups.

Key Studies & References

  1. Acne vulgaris - Prescribing Guideline - Clinical Management in Primary Care - BSW Together (Referencing NICE Guideline NG198)

Frequently Asked Questions (FAQ)

Common questions about Zineryt (FAQ)

Q: Is Zineryt effective for treating cystic or nodular types of acne?

Official product information indicates Zineryt is for the treatment of acne vulgaris. The medication is typically used for mild to moderate acne. A healthcare professional can assess if the treatment is appropriate for severe forms of acne, such as cystic or nodular types.


Q: How long does Zineryt typically take to show noticeable improvement?

While initial improvement may be observed sooner, official administration guidelines indicate that the full benefit of the solution may not be noticed until 10 to 12 weeks of continuous use.


Q: Should Zineryt be applied before or after a sunscreen product in the morning routine?

Administration instructions specify that the medicine should be applied to clean skin and allowed to dry completely first. Administration guidelines indicate other topical products, such as sunscreen, may be applied after the solution has completely dried.


Q: Can Zineryt be used in combination with oral antibiotics for acne treatment?

Using Zineryt in combination with certain other antibiotics carries a risk of cross-resistance to the macrolide group of antibiotics. Regulatory guidelines emphasize the need to inform a healthcare professional of any other antibiotics being used, whether topical or oral.


Q: Are there any known interactions between Zineryt and common vitamin or mineral supplements?

According to the official regulatory documents, formal drug interaction studies involving common vitamin or mineral supplements have not been performed. Official guidelines recommend informing a healthcare professional of all products being used alongside Zineryt.


Q: How is Zineryt different in formulation from acne treatments like clindamycin solution?

Zineryt is classified as a fixed-dose combination product containing the macrolide antibiotic Erythromycin and Zinc Acetate. This distinguishes it from other topical antibiotic solutions used for acne, such as those that contain Clindamycin.


Q: Do research studies support the use of Zineryt for maintaining clear skin after the initial course?

Regulatory documentation notes that a treatment course should not usually exceed six months due to the risk of superinfection by resistant micro-organisms. Official labeling places constraints on prolonged continuous use. Data regarding sustained effects after a successful course is stopped are limited.


Q: What are the official research findings on the long-term safety of Zineryt use?

The primary long-term safety constraint noted in regulatory labeling relates to the potential for developing superinfection by resistant micro-organisms. Because of this risk, the treatment course should not usually exceed six months.


Q: Is Zineryt effective for treating skin conditions other than acne vulgaris?

Zineryt is officially indicated for the treatment of acne, specifically the dominant form of papulo-pustular inflammatory phenomena known as acne vulgaris.


Q: Is Zineryt safe to use on broken skin or open wounds?

Official product information advises that the solution should not be used on broken, sunburned, or sore skin. This constraint helps prevent irritation.


Q: Is it safe to apply Zineryt to the face if a person is also taking an oral antibiotic for a different infection?

Taking any other antibiotics while using Zineryt may promote cross-resistance to macrolides or related antibiotics. It is necessary to inform a healthcare professional of all systemic (oral) antibiotics being used.


Q: Does Zineryt's effectiveness vary based on the severity of the acne (mild vs. moderate)?

Zineryt is officially indicated for the treatment of mild to moderate acne. The product labeling details the overall effectiveness for this range, but it does not specify how the final outcome varies distinctly between mild versus moderate severity levels.


Q: Is it necessary to use a special, non-comedogenic cleanser while treating acne with Zineryt?

Patient information advises that before application, the affected area should be washed with a gentle, non-comedogenic cleanser and patted dry. This step is advised as part of the overall skin preparation for treatment.


Q: What steps should be taken to manage skin dryness or peeling while using Zineryt?

Dryness and peeling are documented as potential, though uncommon, adverse effects. Regulatory-derived patient advice suggests the use of an unfragranced, oil-free or non-comedogenic moisturiser.


Q: What are the signs of a rare, serious allergic reaction to Zineryt?

Rare or serious adverse reactions include Hypersensitivity and Acute generalised exanthematous pustulosis (AGEP). General signs of a severe reaction may include difficulty breathing, coughing, or a red scaly rash.


Q: How would a user recognize the signs of antibiotic resistance while using Zineryt?

Treatment failure may be suspected if the treatment course has been completed and no improvement occurs or if the acne worsens. In such cases, a healthcare professional should be consulted.


Q: Can Zineryt be used safely while pregnant or planning for pregnancy?

The product may be used during pregnancy. If a person is pregnant or planning to become pregnant, official guidelines state consultation with a healthcare professional is recommended before use.


Q: Why must Zineryt not be applied to the chest area while breastfeeding?

The constraint against applying the solution to the chest area while breastfeeding is specifically to prevent accidental ingestion by the infant.


Q: Is Zineryt suitable for people who have a known allergy to penicillin or macrolide antibiotics?

Zineryt is contraindicated if a person has a known hypersensitivity to the active ingredients or to other macrolide antibiotics. However, official information clarifies that allergy to penicillin does not automatically contraindicate Zineryt, as they belong to different antibiotic classes.


Q: What is the proper order for applying Zineryt and a non-medicated facial moisturizer?

The medicine should be applied to the skin first and allowed to dry completely. Only after the solution has dried should a non-medicated facial moisturizer be applied.


Q: Why is Zineryt typically recommended to be applied twice a day, in the morning and evening?

The dosage schedule defined in the regulatory labeling requires application twice a day over the affected area. This frequency is necessary to achieve safe and effective treatment as prescribed.


Q: Why must Zineryt be stored below 25°C or refrigerated after mixing?

The constituted solution must be stored at a temperature not above 25°C to maintain the stability and efficacy of the active ingredients. This storage requirement is necessary to help maintain the solution's effectiveness throughout its 8-week expiry period.


Q: Does Zineryt contain ethanol (alcohol), and is that responsible for the stinging sensation?

Yes, the Zineryt solution contains the excipient Ethanol. The temporary burning or stinging sensation that is sometimes observed upon initial application is attributed to the alcohol base of the solution.


Q: Why is it important to wash and dry the skin completely before applying Zineryt?

The administration guidelines require that the affected area of skin be washed and gently dried before application. This step is required as part of the administration guidelines.


Q: Does the zinc ingredient in Zineryt help with reducing skin oiliness?

The zinc component contributes a supportive role with astringent properties. This component has been noted in patient information to help regulate or control skin oiliness.


Q: Are there non-active ingredients in the Zineryt solution that are potential allergens?

Zineryt is contraindicated if a person has a known hypersensitivity to the active ingredients or to any of the product's excipients. The excipients include Di-isopropyl sebacate and Ethanol.


Q: Is Zineryt suitable for individuals with very sensitive skin, or will it cause more irritation?

The solution is associated with local skin reactions, including irritation, dry skin, and burning. Individuals with sensitive skin may experience increased irritation.


Q: Why does the Zineryt bottle need to be sealed tightly after every application?

The administration instructions require the cap to be replaced firmly after each use. This step is part of the administration instructions to help protect the solution and maintain its stability and efficacy over the treatment period.


Q: What is the minimum recommended time interval between two applications of Zineryt?

The regulatory guidelines specify that if an application is missed, it should be applied when remembered, but there must be a gap of about three hours before the next scheduled application. This is the minimum required interval for safe application.

How should Zineryt be stored and disposed of?

Official Storage and Disposal Requirements

The storage and disposal instructions for Zineryt (erythromycin/zinc acetate cutaneous solution) are strictly defined by regulatory documents, particularly concerning the prepared solution.

  • Temperature: The constituted solution must be stored at a temperature not above 25 C.
  • Stability Limit: After the pharmacist has prepared the solution, it must be used within 8 weeks and discarded thereafter.
  • Child Safety: The medicine must always be kept out of the sight and reach of children.
  • Disposal: Do not throw away the medicine via household waste or wastewater. Unused or expired Zineryt must be returned to a pharmacist for proper disposal, a measure designed to help protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zineryt found in:

A-Z Index: